AN
AN2 Therapeutics, Inc.
ANTX · NASDAQ
$5.73 -4.82% (-$0.29)
1M -2.39%
Market Cap $206.4M
P/E Ratio -
Div. Yield -
ROE 53.52%
Bulios Fair Price
$3.87
32.5% downside
Current Price
$5.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
71 /100
Cheap P/B 2.72x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 17.75%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 51.01%
ROE 53.52%
ROA 44.41%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 14.32x
Int. coverage N/A
Stability
57 /100
Moderate Beta -0.99x
EPS volatility 19.25%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Eric E. Easom
Employees
21
Headquarters
Menlo Park
Upcoming events
05 NOV
Earnings
Upcoming earnings report